Intellectual Property,
Health Care & Hospital Law
Jul. 23, 2021
Jury gives Plexxikon $178M in patent battle with Novartis
A Novartis spokesman acknowledged that the company infringed on Plexxikon’s patents for skin cancer drugs and that it might have to pay royalties on sales.
Plexxikon, a Berkeley based biotechnology company, was awarded $178 million on Thursday in a patent infringement court battle against Swiss pharmaceutical giant Novartis over skin cancer drugs.
"We are delighted with the jury's very careful verdict and that Plexxikon's groundbreaking innovations have been vindicated," Plexxikon's attorney Daralyn J. Durie of Durie Tangri LLP said in an email. "We look forward to discussing with the ...
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
Or access this article for $45
(Purchase provides 7-day access to this article. Printing, posting or downloading is not allowed.)
Already a subscriber?
Sign In
